ANAPTYSBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.23 USD | +1.86% |
|
-0.42% | +22.46% |
| Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
| Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
Presenter SpeechChia Peck Wong (Analysts)Good afternoon, everyone. Thank you very much for att...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Calendar
2024-06-11
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
25.75
USD
Average target price
43.67
USD
Spread / Average Target
+69.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.46% | 703M | |
| +2.97% | 108B | |
| +10.21% | 105B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -7.05% | 18.64B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- Transcript : AnaptysBio, Inc. Presents at Bank of America Merrill Lynch 2018 Healthcare Conference, May-16-2018 04